Open Menu
Meetings & Education
Meetings & Education
Research & Data
Practice & Patients
Career Development
News & Initiatives
Get Involved
The MATRiX trial: A multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1–refractory Merkel cell carcinoma.
Background: Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer driven by UV mutations or the Merkel cell polyomavirus (MCPyV).It is aggressive, with a high Ki-67 proliferative index.Despite an initial high response rate (~55%) to PD-1 pathway inhibitors, >50% of patients exhibit primary or acquired resistance.ATR (ataxia telangiectasia and Rad3-related) kinase, a critical cell cycle checkpoint regulator, ensures genome fidelity in cancer cells experiencing high replication stress, including MCC.Our preclinical findings suggest anticancer activity of ATR inhibition via transcriptional induction of NF-κB-associated proinflammatory mechanisms.The potent, selective, orally administered ATR inhibitor tuvusertib (M1774) has shown antitumor activity in patients with unresectable solid cancers in Phase I trials, with a recommended Phase II dose of 180 mg daily on an intermittent schedule.We hypothesize that tuvusertib ± anti-PD-(L)1,may induce tumor regression in advanced anti-PD-(L)1-refractory MCC.
Methods: The multicenter, randomized Phase II MATRiX trial tests the safety and efficacy of tuvusertib monotherapy (Arm 1) and tuvusertib plus avelumab (Arm 2) in patients with metastatic MCC refractory to PD-(L)1 blockade. Patients with progressive disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 within 120 days of their last anti-PD-(L)1 therapy are eligible. Subjects randomized to Arm 1 receive tuvusertib 180 mg QD on days 1-14 of each 21-day cycle. Subjects in Arm 2 also receive avelumab 1600 mg IV on day 1 of each 21-day cycle. Imaging studies performed 9 weeks after treatment initiation and every 12 weeks thereafter will be assessed per RECIST v1.1. Patients in Arm 1 with progressive disease may receive tuvusertib + avelumab. Treatment-emergent adverse events are graded per Common Terminology Criteria for Adverse Events version 5.0. The primary endpoint is progression-free survival (PFS). Between June 2024 and January 2025, 13 subjects were enrolled across 10 centers. With a targeted enrollment of 50 patients, this trial has 83% power to observe a statistically significant (one-sided level of 10%) difference in PFS if the true hazard ratio for failure is 2.0. A stratified (primary vs. acquired resistance) log-rank test will be used, and binary outcomes will be compared using a Mantel-Haenzel test. A Wieand-like futility rule will be used for an interim analysis after the 23rd event occurs. Tumor biopsies, blood, and stool specimens will be profiled to gain integrated insight into transcriptomic, proteomic, and metabolic signatures associated with immune-mediated therapeutic outcomes. This orthogonal approach to solid tumor immunotherapy, relevant to analogous cancers, will guide future combination strategies to better harness the anti-tumor immune response.
Disclaimer
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Author Details
Rashmi Bhakuni
University of Washington Medicine Dermatology, Seattle, WA
Authors chevron_right
Associated Organizations chevron_right
Abstract Details
Meeting
2025 ASCO Annual Meeting
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
View MoreAbstract Disclosure
open_in_new
Similar Abstracts
text_snippet
Abstract
2022 ASCO Annual Meeting
First Author: Meiling Xu
text_snippet
Abstract
2021 ASCO Annual Meeting
First Author: Thorsten Oliver Goetze
text_snippet
Abstract
2022 ASCO Annual Meeting
First Author: Sophie Cousin
text_snippet
Abstract
2023 ASCO Annual Meeting
First Author: Pengfei Xing
Download
Your Privacy
ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.
Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.
For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.
Allow All
Manage Consent Preferences
Essential Website Cookies
Always Active
These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.
They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.
You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.
Cookies Details‎
Performance and Functionality Cookies
Performance and Functionality Cookies
These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.
All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.
Cookies Details‎
Personalization and Analytics Cookies
Personalization and Analytics Cookies
These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.
These cookies may be set by us or by third party providers whose services we have added to our websites.
These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.
Cookies Details‎
Advertising Cookies and Social Media Cookies
Advertising Cookies and Social Media Cookies
Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.
Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.
These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.
If you do not allow these cookies, you may experience less targeted advertising.
Cookies Details‎
Back Button
Cookie List
Search Icon
Filter Icon
Clear
checkbox labellabel
ApplyCancel
ConsentLeg.Interest
checkbox labellabel
checkbox labellabel
checkbox labellabel
View Cookies
Name
cookie name
Save Settings
